JP6754828B2 - ピリジン及びピリミジン誘導体 - Google Patents
ピリジン及びピリミジン誘導体 Download PDFInfo
- Publication number
- JP6754828B2 JP6754828B2 JP2018506863A JP2018506863A JP6754828B2 JP 6754828 B2 JP6754828 B2 JP 6754828B2 JP 2018506863 A JP2018506863 A JP 2018506863A JP 2018506863 A JP2018506863 A JP 2018506863A JP 6754828 B2 JP6754828 B2 JP 6754828B2
- Authority
- JP
- Japan
- Prior art keywords
- benzamide
- tert
- butyl
- methyl
- propan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- AWEIUYNPTFMPPS-UHFFFAOYSA-N CC(C)(C(F)(F)F)NC(c1cc(I)cc(-c(cc2)ccc2Cl)c1)=O Chemical compound CC(C)(C(F)(F)F)NC(c1cc(I)cc(-c(cc2)ccc2Cl)c1)=O AWEIUYNPTFMPPS-UHFFFAOYSA-N 0.000 description 1
- BTQSNPMFNMKKED-UHFFFAOYSA-N CC(C)(C)NC(c1cc(-c(cc2)ccc2Cl)cc(-c2c(C)ccnc2)c1)=O Chemical compound CC(C)(C)NC(c1cc(-c(cc2)ccc2Cl)cc(-c2c(C)ccnc2)c1)=O BTQSNPMFNMKKED-UHFFFAOYSA-N 0.000 description 1
- RXJITZUCKZVHCK-UHFFFAOYSA-N CC(C)(C)NC(c1cc(-c2c(C)ncnc2)cc(-c(cc2)ccc2Cl)c1)=O Chemical compound CC(C)(C)NC(c1cc(-c2c(C)ncnc2)cc(-c(cc2)ccc2Cl)c1)=O RXJITZUCKZVHCK-UHFFFAOYSA-N 0.000 description 1
- KCIHZYZBUNMRJZ-UHFFFAOYSA-N CC(C)(C)NC(c1cc(B2OC(C)(C)C(C)(C)O2)cc(-c(cc2)ccc2F)c1)=O Chemical compound CC(C)(C)NC(c1cc(B2OC(C)(C)C(C)(C)O2)cc(-c(cc2)ccc2F)c1)=O KCIHZYZBUNMRJZ-UHFFFAOYSA-N 0.000 description 1
- CRIPULLKBSDLQK-UHFFFAOYSA-N CC(C)c(ncnc1)c1-c1cc(I)cc(C(NC(C)(C)C#N)=O)c1 Chemical compound CC(C)c(ncnc1)c1-c1cc(I)cc(C(NC(C)(C)C#N)=O)c1 CRIPULLKBSDLQK-UHFFFAOYSA-N 0.000 description 1
- BNXOKCYXMRXNJX-UHFFFAOYSA-N CCc(ncnc1)c1-c1cc(-c(cc2)ccc2F)cc(C(NC(C)(C)C)=O)c1 Chemical compound CCc(ncnc1)c1-c1cc(-c(cc2)ccc2F)cc(C(NC(C)(C)C)=O)c1 BNXOKCYXMRXNJX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15180759.1 | 2015-08-12 | ||
| EP15180759 | 2015-08-12 | ||
| PCT/EP2016/068919 WO2017025523A1 (en) | 2015-08-12 | 2016-08-09 | Pyridine and pyrimidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522916A JP2018522916A (ja) | 2018-08-16 |
| JP2018522916A5 JP2018522916A5 (https=) | 2019-09-26 |
| JP6754828B2 true JP6754828B2 (ja) | 2020-09-16 |
Family
ID=53835950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506863A Expired - Fee Related JP6754828B2 (ja) | 2015-08-12 | 2016-08-09 | ピリジン及びピリミジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10005736B1 (https=) |
| EP (1) | EP3334727B1 (https=) |
| JP (1) | JP6754828B2 (https=) |
| CN (1) | CN107922391B (https=) |
| AR (1) | AR105662A1 (https=) |
| TW (1) | TW201718499A (https=) |
| WO (1) | WO2017025523A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019517476A (ja) * | 2016-05-27 | 2019-06-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｅａａｔ３阻害剤としてのピラゾール化合物 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107207449B (zh) | 2015-04-23 | 2020-11-10 | 豪夫迈·罗氏有限公司 | 用于治疗精神障碍的四唑衍生物 |
| CN108137566B (zh) | 2015-10-06 | 2021-05-25 | 豪夫迈·罗氏有限公司 | 三唑衍生物 |
| WO2017072083A1 (en) * | 2015-10-28 | 2017-05-04 | F. Hoffmann-La Roche Ag | Pyridine or pyrimidine derivatives |
| EP3411365B1 (en) | 2016-02-02 | 2019-11-20 | H. Hoffnabb-La Roche Ag | Pyrazol-pyridine derivatives as eaat3 inhibitors |
| CN109563049B (zh) | 2016-10-14 | 2022-11-29 | 豪夫迈·罗氏有限公司 | 作为eaat3抑制剂的咪唑化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2658362A1 (en) * | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| CA2737038A1 (en) * | 2008-09-18 | 2010-03-25 | Evotec Ag | Amide compounds, compositions and uses thereof |
| ES2534199T3 (es) * | 2008-10-31 | 2015-04-20 | Merck Sharp & Dohme Corp. | Antagonistas del receptor P2X3 para el tratamiento del dolor |
-
2016
- 2016-08-09 CN CN201680044820.8A patent/CN107922391B/zh not_active Expired - Fee Related
- 2016-08-09 EP EP16748125.8A patent/EP3334727B1/en not_active Not-in-force
- 2016-08-09 JP JP2018506863A patent/JP6754828B2/ja not_active Expired - Fee Related
- 2016-08-09 WO PCT/EP2016/068919 patent/WO2017025523A1/en not_active Ceased
- 2016-08-10 AR ARP160102450A patent/AR105662A1/es unknown
- 2016-08-11 TW TW105125661A patent/TW201718499A/zh unknown
-
2018
- 2018-02-08 US US15/891,922 patent/US10005736B1/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019517476A (ja) * | 2016-05-27 | 2019-06-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｅａａｔ３阻害剤としてのピラゾール化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107922391A (zh) | 2018-04-17 |
| EP3334727B1 (en) | 2019-05-15 |
| US10005736B1 (en) | 2018-06-26 |
| US20180162824A1 (en) | 2018-06-14 |
| WO2017025523A1 (en) | 2017-02-16 |
| HK1251226A1 (zh) | 2019-01-25 |
| TW201718499A (zh) | 2017-06-01 |
| CN107922391B (zh) | 2020-09-25 |
| EP3334727A1 (en) | 2018-06-20 |
| AR105662A1 (es) | 2017-10-25 |
| JP2018522916A (ja) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6754828B2 (ja) | ピリジン及びピリミジン誘導体 | |
| JP6518789B2 (ja) | 精神障害の処置において使用するためのテトラゾール誘導体 | |
| JP6877359B2 (ja) | イミダゾール誘導体 | |
| CN102361853A (zh) | 甲苯胺磺酰胺及其用途 | |
| JP6849668B2 (ja) | ピリジン又はピリミジン誘導体 | |
| JP6846363B2 (ja) | ２−フェニル−６−イミダゾリル−ピリジン−４−カルボキサミド誘導体及びそのｅａａｔ３阻害剤としての使用 | |
| JP6831376B2 (ja) | トリアゾール誘導体 | |
| JP6905988B2 (ja) | Ｅａａｔ３阻害剤としてのピラゾール−ピリジン誘導体 | |
| JP2018531253A6 (ja) | トリアゾール誘導体 | |
| JP6936257B2 (ja) | Ｅａａｔ３阻害剤としてのピラゾール化合物 | |
| EP3526201A1 (en) | Imidazole compounds as eaat3 inhibitors | |
| HK1251226B (zh) | 吡啶和嘧啶衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190805 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190805 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200728 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200722 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200824 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6754828 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |